TScan Therapeutics, Inc. (TCRX) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- S&P 500 futures steady after midterm rally; Nasdaq lags on chip weakness
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts TCRX Hot Sheet
Join SI Premium – FREE
TScan Therapeutics, Inc. (NASDAQ: TCRX) reported Q3 EPS of ($0.67), $0.05 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $3.36 million versus the consensus estimate of $3.66 million.
For earnings history and earnings-related data on TScan Therapeutics, Inc. (TCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 1stdibs.Com, Inc. (DIBS) Tops Q3 EPS by 2c ; Offers Guidance
- Middleby Corp (MIDD) Tops Q3 EPS by 31c, Beats on Revenue; Offers FY26 Guidance
- LifeStance Health Group, Inc. (LFST) Tops Q3 EPS by 2c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
